All News

ACR20 Capitol

A Convergence of Ideas: COVID19 and ACR

Kathryn H. Dao, M.D.

Since the beginning of the pandemic, rheumatologists scrambled to figure out how the SARS-CoV-2 virus will affect their patients with immune mediated inflammatory diseases (IMID). Meeting the needs of patients, managing a practice, and trying to balance a home life have many doctors stressed.

Read Article
COVID.Flu_.Virus_.jpg (keep)

Infection and Rheumatic Diseases: A New Dawn

Mrinalini Dey, MD

Infection in the setting of autoimmune rheumatic disease (ARD) has been the subject of increasing research and clinical interest for decades. Despite the huge burden of infection in patients with ARDs, this area of research has really been catapulted to the centre-stage of research agendas and coverage at congresses, including ACR 2020, with the arrival of the coronavirus disease 2019 (COVID-19) pandemic.

Read Article
podcast logo

RheumNow Podcast – ACR 20 is Coming to Town (10.30.20)

Jack Cush, MD

Dr Jack Cush overviews the RheumNow commitment, upcoming bonus coverage of ACR20 and the good news and journal reports from the past week on RheumNow.com

Read Article
FDA.jpg (keep)

FDA Hearing on COVID-19 Vaccines

Jack Cush, MD

Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve

Read Article
podcast logo

RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.

Read Article
COVID.virus_.corona.jpg (keep)

Remdesivir FDA Approved for Hospitalized COVID-19

Jack Cush, MD

The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.

Read Article
Covid lung pneumonia corona (keep)

Clinical Trial Boom or Bust in Severe COVID-19

Jack Cush, MD

A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.



Remdesivir

Read Article
Our daily update is published. States reported record numbers of tests (1.5 million) and cases (116k). Hospitalizations continue their sharp rise. The death toll was 1,124. https://t.co/z3gxwP6EaC
The COVID Tracking Project COVID19Tracking ( View Tweet)
#LTF Please wear your mask https://t.co/dzN0SDLb0T
Dr. John Cush RheumNow ( View Tweet)
Spanish cross-sectional study of 2,102 Rheumatic patients compared meds to COVID risk and showed Denosumab (0.58), zoledronate (0.62), calcium were negatively associated with COVID-19. Why? is it that they are less "sick"? https://t.co/BNbwsCz0rA

Links:

Dr. John Cush RheumNow ( View Tweet)

Racial/ethnic minorities with rheumatic Dz(RD) & COVID had increased odds of hospitalization & ventilatory support. 1,324 pts w/ RD+COVID, 36% hospitalized, 6% died. Compared to whites- Blacks Latinos & Asians had higher risk of hospital (OR=2.7, 1.7, 2.7) https://t.co/OGmarAfzLM

Links:

Dr. John Cush RheumNow ( View Tweet)

Cohort study (n 186) from NYC shows that patients with COVID and autoimmune disease were not at an increased risk for a ICU admission, intubation, or death (adjOR 0.79, 95%CI 0.37-1.67). AI pts had more comorbidities (26% vs. 13%), immunosuppressives https://t.co/TMCcKbns0f

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is UP! ACR 20 is Coming to Town - news on melanoma, COVID biologics & autoantibodies, Hepatitis & JAKs, Safety of nintedinib, upcoming ACR2020. Watch it here> https://t.co/np5aFCo9FB or listen on Apple> https://t.co/FHJv01AAbC or Android> https://t.co/qxuBmiNxU0

Links:

Dr. John Cush RheumNow ( View Tweet)

QD104 - You Are So Not Disabled QD Clinic - Lessons from the clinic Grappling with Disability Letter Requests Features Dr. Jack Cush https://t.co/Vg5i9rHyKN

Links:

Dr. John Cush RheumNow ( View Tweet)

Autoantibodies can be found in COVID-19 ptas (including ANA, RF, -RNP centromere and antibobides against phospholipids (3/52), prothrombin (2/52), and c-ANCA (2/52)) (THIS IS A PREPRINT) https://t.co/kN6hVMiNt3 https://t.co/4yNJJhOxXP

Links:

Dr. John Cush RheumNow ( View Tweet)

ACTIV-1 run by the ⁦@NIH⁩ will test rheum drugs infliximab and abatacept in COVID-19. This is great news. https://t.co/IITzGTuxEC

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

Randomized trial of 491 probable nonhospitalized COVID-19 pts shows that HCQ (given 800 mg, followed by 600 mg in 6 -8 hrs, then 600 mg qd x 4d) or placebo shows no reduction in symptom severity in outpatients with early, mild COVID-19.https://t.co/yVWGRr6jfr

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA approved its 1st drug to treat COVID-19 - the antiviral drug Veklury (remdesivir) for for acute care treatment of COVID-19 requiring hospitalization. Approval based on 3 clinical trials showing clinical improvement, but no change in mortality rates. https://t.co/IrA7oKMuGq

Links:

Dr. John Cush RheumNow ( View Tweet)

Study from NY shows that Death rates from COVID-19 have dropped (in hospitalized pts) from a high of 27% down to 3%. Partly because a younger, healthier are now getting infected, arriving @ hospital w/ less-severe Sxs. Also improved COVID medical care https://t.co/8aFuVHUDjY

Links:

Dr. John Cush RheumNow ( View Tweet)

#LTF Listen to Fauci

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×